Standard Orexin Antagonist Dosing
Orexin antagonists rely on CYP3A4 for normal clearance.
- CYP3A4: Primary clearance enzyme (hepatic + gut wall)
- ~12 h: Typical half-life (suvorexant-class)
- 1.0×: Baseline plasma level (reference exposure)
- 10–20 mg: Standard bedtime dose (label-recommended)
Orexin receptor antagonism
Suvorexant, lemborexant block wake-promoting orexin signaling.
CYP3A4 as sole clearance route
Nearly all dose is oxidized by hepatic CYP3A4.
Narrow therapeutic window
Small exposure shifts change sedation meaningfully.
CYP3A4 Inhibitor Co-Administration
An inhibitor occupies CYP3A4, slowing drug breakdown.
- ≥5×: Strong inhibitor AUC rise (ketoconazole-class)
- 2–5×: Moderate inhibitor rise (diltiazem-class)
- Reduce dose: Label guidance (strong/moderate inhibitors)
- Hours: Onset of effect (reversible binding)
Competitive enzyme blockade
Inhibitor molecules occupy the CYP3A4 active site.
Common perpetrators
Azoles, macrolides, ritonavir strongly inhibit CYP3A4.
Dose-adjustment rule
Strong inhibitors mandate lowest orexin antagonist dose.
Elevated Plasma Exposure & Sedation Risk
Accumulated drug raises next-day impairment risk.
- ↑ with AUC: Next-day somnolence risk (dose-dependent)
- Elevated: Driving impairment risk (residual sedation)
- Rare, additive risk: Respiratory depression (with other CNS depressants)
- Avoid or reduce dose: Recommended action (strong inhibitor + label)
Excess CNS depression
High plasma levels prolong sedative and hypnotic effects.
Next-day residual effect
Morning drowsiness and impaired alertness can persist.
Combined depressant risk
Alcohol or opioids compound sedation further.
CYP3A4 Inducer Co-Administration
An inducer boosts CYP3A4 abundance, speeding clearance.
- ≥80%: Strong inducer AUC drop (rifampin-class)
- 50–80%: Moderate inducer drop (efavirenz-class)
- Days–weeks: Onset of induction (new protein synthesis)
- Avoid combination: Label guidance (strong inducers)
Transcriptional upregulation
PXR activation increases CYP3A4 enzyme abundance.
Common perpetrators
Rifampin, carbamazepine, St. John's Wort strongly induce.
Slow onset and offset
Induction builds and resolves over one to two weeks.
Reduced Efficacy & Subtherapeutic Dosing
Falling plasma levels can leave insomnia undertreated.
- <0.6× baseline: Subtherapeutic threshold (efficacy risk zone)
- Diminished: Sleep-onset benefit (low occupancy)
- Avoid strong inducers: Recommended action (or use alternative agent)
- Clinical response: Monitoring approach (no routine drug levels)
Insufficient receptor occupancy
Low plasma drug fails to block orexin signaling.
Treatment failure risk
Patients may report the medication stopped working.
Prescribing takeaway
Avoid strong inducers or switch to unaffected agent.